nach oben

Erschienen in:

26.08.2019 | Review Article

Radiotherapy after skin-sparing mastectomy with immediate breast reconstruction in intermediate-risk breast cancer

Indication and technical considerations

verfasst von: Thomas Hehr, René Baumann, Wilfried Budach, Marciana-Nona Duma, Jürgen Dunst, Petra Feyer, Rainer Fietkau, Wulf Haase, Wolfgang Harms, David Krug, Marc D. Piroth, Felix Sedlmayer, Rainer Souchon, Frederick Wenz, Rolf Sauer, Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO)

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Skin-sparing (SSME) and nipple-sparing mastectomy (NSME) were developed to improve the cosmetic results for breast cancer (BC) patients, both allowing for immediate breast reconstruction. Recommendations for post-mastectomy radiotherapy (PMRT) are primarily derived from trials where patients were treated by standard mastectomies. Due to their more conservative character, SSME and especially NSME potentially leave more glandular tissue at risk for subclinical disease.

Methods

Rates and sites of locoregional failures following SSME and NSME plus/minus reconstruction were analyzed regarding tumor stage and biological risk factors. In particular, the role of PMRT in “intermediate”-risk and early stage high-risk breast cancer patients was revisited. Implications on targeting and dose delivery of PMRT were critically reviewed.

Results

The value of PMRT in stage III BC remains undisputed. For node-negative BC patients, the majority of reports classify clinical and biological features such as tumor size, close surgical margins, premenopausal status, multicentricity, lymphangiosis, triple-negativity, HER2-overexpression, and poor tumor grading as associated with higher rates of locoregional relapse, thus, building an “intermediate” risk group. Surveys revealed that the majority of radiation oncologists use risk-adaptive models also considering the number of coinciding factors for the estimation of recurrence probability following SSME and NSME. Constellations with a 10-year locoregional recurrence risk of >10% are usually triggering the indication for PMRT. There was no common belief that the amount of residual tissue, e.g., tissue thickness over flaps, serves as additional decision aid. Modern treatment planning can ensure optimal dose distribution for PMRT in almost all patients with SSME. There are no reliable data supporting a reduction of the treatment volume from the CTV chest wall, e.g., to the nipple-areola complex, to the dorsal aspect behind the implant volume, the pectoralis muscle, nor the regional interpectoral, axillary, or complete regional lymph nodes only. The omission of a skin bolus in intermediate-risk BC does not compromise oncological safety.

Conclusions

For intermediate-risk as well as early stage high-risk BC patients, the DEGRO Breast Cancer Expert Panel recommends the use of PMRT following SSME and NSME when a 10-year locoregional recurrence risk is likely to be greater than 10%, as estimated by clinical and biological risk factors. Subvolume-only radiation is discouraged outside of trials. The impact of adequate systemic treatment and the value of radiotherapy on optimal locoregional tumor control, with the goal of less than 5% LRR at 10-years follow-up, has to be verified in prospective trials.

Manning AT, Sacchini VS (2016) Conservative mastectomies for breast cancer and risk-reducing surgery: The Memorial Sloan Kettering Cancer Center experience. Gland Surg 5(1):55–62. https://doi.org/10.3978/j.issn.2227-684X.2015.10.02 CrossRefPubMedPubMedCentral

Ananthakrishnan P, Feldman S (2012) Nipple-sparing mastectomy: indications, oncologic safety. Minerva Chir 67(3):257–270 (Review)PubMed

Recht A et al (2016) Postmastectomy radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology focused Guideline update. Pract Radiat Oncol 6:219–234CrossRef

Wenz F, Budach W (2017) Personalized radiotherapy for invasive breast cancer in 2017: National S3 guidelines and DEGRO and AGO recommendations. Strahlenther Onkol 193(8):601–603PubMedCrossRef

EBCTCG (Early Breast Cancer Trialists’ Collaborative Group) (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383(9935):2127–2135. https://doi.org/10.1016/S0140-6736(14)60488-8.-35 CrossRef

Garcia-Etienne CA, Cody Iii HS 3rd, Disa JJ et al (2009) Nipple-sparing mastectomy: Initial experience at the Memorial Sloan-Kettering Cancer Center and a comprehensive review of literature. Breast J 15:440–449PubMedCrossRef

Krug D, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Hehr T, Piroth MD, Sedlmayer F, Souchon R, Wenz F, Sauer R, Breast Cancer Expert Panel of the German Society of Radiation Oncology (2018) Neoadjuvant chemotherapy for breast cancer-background for the indication of locoregional treatment. Strahlenther Onkol 194(9):797–805. https://doi.org/10.1007/s00066-018-1329-8 CrossRefPubMed

Krug D, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Hehr T, Piroth MD, Sedlmayer F, Souchon R, Wenz F, Sauer R, Breast Cancer Expert Panel of the German Society of Radiation Oncology (2018) Individualization of post-mastectomy radiotherapy and regional nodal irradiation based on treatment response after neoadjuvant chemotherapy for breast cancer : A systematic review. Strahlenther Onkol 194(7):607–618. https://doi.org/10.1007/s00066-018-1270-x CrossRefPubMed

Rowell NP (2009) Radiotherapy to the chest wall following mastectomy for node-negative breast cancer: A systematic review. Radiother Oncol 91:23–32PubMedCrossRef

10.

Velikova G, Williams LJ et al (2018) Quality of life results after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. Lancet Oncol 19:1516–1529PubMedCrossRef

11.

Jagsi R, Raad RA, Goldberg S et al (2005) Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: Implications for postmastectomy radiation. Int J Radiat Oncol Biol Phys 62:1035–1039PubMedCrossRef

12.

Abdulkarim BS, Cuartero J, Hanson J, Deschênes J, Lesniak D, Sabri S (2011) Increased risk of locoregional recurrence for women with T1–2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol 29(21):2852–2858PubMedPubMedCentralCrossRef

13.

Abi-Raad R, Boutrus R, Wang R et al (2011) Patterns and risk factors of locoregional recurrence in T1–T2 node negative breast cancer patients treated with mastectomy: Implications for postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys 81:e151–e157PubMedPubMedCentralCrossRef

14.

Wang J et al (2011) Adjuvant chemotherapy and radiotherapy in triple-negativ breast cancer: A prospective randomized controlled multi-canter trial. Radiother Oncol 100:200–204PubMedCrossRef

15.

Mamtani A, Patil S, Stempel MM, Morrow M (2017) Are there patients with T1 to T2, lymph node-negative breast cancer who are “high-risk” for locoregional disease recurrence? Cancer 123(14):2626–2633. https://doi.org/10.1002/cncr.30658 CrossRefPubMedPubMedCentral

16.

Wu X, Baig A, Kasymjanova G, Kafi K, Holcroft C, Mekouar H, Carbonneau A, Bahoric B, Sultanem K, Muanza T (2016) Pattern of local recurrence and distant metastasis in breast cancer by molecular subtype. Cureus 8(12):e924. https://doi.org/10.7759/cureus.924 CrossRefPubMedPubMedCentral

17.

Laurberg T, Tramm T, Nielsen T, Alsner J, Nord S, Myhre S, Sørlie T, Leung S, Fan C, Perou C, Gelmon K, Overgaard J, Voduc D, Prat A, Cheang MCU (2018) Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy—Results from two independent randomized trials. Acta Oncol 57(1):38–43PubMedCrossRef

18.

Galimberti V, Morigi C, Bagnardi V et al (2018) Oncological outcomes of Nopple-sparing mastectomy: A single center experience of 1989 patients. Ann Surg Oncol 25:3849–3857PubMedCrossRef

19.

Marta GN et al (2017) Postoperative radiation therapy after nipple-sparing or skin-sparing mastectomy: A survey of European, North American, and South American practices. Breast J 23:26–33PubMedCrossRef

20.

Torresan RZ, dos Santos CC, Okamura H, Alvarenga M (2005) Evaluation of residual glandular tissue after skin-sparing mastectomies. Ann Surg Oncol 12:1037–1044PubMedCrossRef

21.

Nguyen K, Mackenzie P, Allen A, Dreosti M, Morgia M, Zissiadis Y, Lamoury G, Windsor A (2017) Breast interest group faculty of radiation oncology: Australian and New Zealand patterns of practice survey on breast radiotherapy. J Med Imaging Radiat Oncol 61(4):508–516. https://doi.org/10.1111/1754-9485.12566 CrossRefPubMed

22.

Vargo JA et al (2015) RTOG chest wall contouring guidelines for post-mastectomy radiation therapy: Is it evidence-based? Int J Radiat Oncol Biol Phys 93(2):266–267PubMedCrossRef

23.

Slavin SA, Love SM, Goldwyn RM (1994) Recurrent breast cancer following immediate reconstruction with myocutaneous flaps. Plast Reconstr Surg 93(6):1191–1204PubMedCrossRef

24.

Gilliland MD, Barton RM, Copeland EM 3rd (1983) The implications of local recurrence of breast cancer as the first site of therapeutic failure. Ann Surg 197(3):284–287PubMedPubMedCentralCrossRef

25.

Donegan WL, Perez-Mesa CM, Watson FR (1966) A biostatistical study of locally recurrent breast carcinoma. Surg Gynecol Obstet 122(3):529–540PubMed

26.

Noone RB, Frazier TG, Noone GC, Blanchet NP, Murphy JB, Rose D (1994) Recurrence of breast carcinoma following immediate reconstruction: A 13-year review. Plast Reconstr Surg 93(1):96–106PubMedCrossRef

27.

Langstein HN, Cheng MH, Singletary SE, Robb GL, Hoy E, Smith TL, Kroll SS (2003) Breast cancer recurrence after immediate reconstruction: patterns and significance. Plast Reconstr Surg 111(2):712–720 (Discussion 721–722)PubMedCrossRef

28.

Chang JS, Lee J, Chun M et al (2018) Mapping patterns of locoregional recurrence following contemporary treatment with radiation therapy for breast cancer: A multi-institutional validation study of the ESTRO consensus guideline on clinical target volume. Radiother Oncol 126(1):139–147PubMedCrossRef

29.

Friedel G, Kuipers T, Engel C, Schopf C, Veit S, Zoller J, Kyriss T, Greulich M, Toomes H (2005) Full-thickness chest wall resection for locally recurrent breast cancer. Thorac Surg Sci 22:2

30.

van der Pol CC, van Geel AN, Menke-Pluymers MB, Schmitz PI, Lans TE (2009) Prognostic factors in 77 curative chest wall resections for isolated breast cancer recurrence. Ann Surg Oncol 16(12):3414–3421PubMedPubMedCentralCrossRef

31.

Levy Faber D, Fadel E, Kolb F, Delaloge S, Mercier O, Mussot S, Fabre D, Dartevelle P (2013) Outcome of full-thickness chest wall resection for isolated breast cancer recurrence. Eur J Cardiothorac Surg 44(4):637–642. https://doi.org/10.1093/ejcts/ezt105 CrossRefPubMed

32.

Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Biete Sola A, Kirova YM, Pignol JP, Remouchamps V, Verhoeven K, Weltens C, Arenas M, Gabrys D, Kopek N, Krause M, Lundstedt D, Marinko T, Montero A, Yarnold J, Poortmans P (2015) ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother Oncol 114(1):3–10. https://doi.org/10.1016/j.radonc.2014.11.030 CrossRefPubMed

33.

Ho CM et al (2003) Skin involvement in invasive breast carcinoma: safety of skin sparing mastectomy. Ann Surg Oncol 10:102–107PubMedCrossRef

34.

Oreccia R (2016) The use of postoperative radiation after nipple sparing mastectomy. Gland Surg 5(1):63–68

35.

Kneubil MC, Lohsiriwat V, Curigliano G et al (2012) Risk of locoregional recurrence in patients with falsenegative frozen section or close margins of retroareolar specimen in nipple-sparing mastectomy. Ann Surg Oncol 19:4117–4123PubMedCrossRef

36.

Petit JY, Veronesi U, Orecchia R et al (2012) Risk factors associated with recurrence after nipple-sparing mastectomy for invasive and intraepithelial neoplasia. Ann Oncol 23:2053–2058PubMedCrossRef

37.

Zakhireh J, Fowble B, Esserman LJ (2010) Application of screening principles to the reconstructed breast. J Clin Oncol 28(1):173–180. https://doi.org/10.1200/JCO.2008.21.7588 CrossRefPubMed

38.

Yoo H, Kim BH, Kim HH et al (2014) Local recurrence of breast cancer in reconstructed breasts using tram flap after skin-sparing mastectomy: Clinical and imaging features. Eur Radiol 24(9):2220–2226PubMedCrossRef

39.

Liang TJ, Wang BW, Liu SI et al (2013) Recurrence after skin-sparing mastectomy and immediate transverse rectus abdominis musculocutaneous flap reconstruction for invasive breast cancer. World J Surg Oncol 11(1):194PubMedPubMedCentralCrossRef

40.

Leif J et al (2014) The credentialing process for the NSABP B-51/RTOG 1304 phase 3 randomized clinical trial abstract RTOG. Int J Radiat Oncol Biol Phys 90(1):S940CrossRef

41.

Bjöhle J, Onjukka E, Rintelä N, Eloranta S, Wickman M, Sandelin K, Gagliardi G, Liljegren A (2019) Post-mastectomy radiation therapy with or without implant-based reconstuction is safe in terms of clinical target volume coverage and survival—A matched cohort study. Radiother Oncol 131:229–236. https://doi.org/10.1016/j.radonc.2018.07.005 CrossRefPubMed

42.

Liljegren A, Unukovych D, Gagliardi G et al (2014) No difference in dose distribution in organs at risk in postmastectomy radiotherapy with or without breast implant reconstruction. Radiat Oncol 9:14. https://doi.org/10.1186/1748-717X-9-14 CrossRefPubMedPubMedCentral

43.

Ayoub Z et al (2017) Radiotherapy after skin-sparing mastectomy and placement of a tissue expander: Effectiveness of a coordinated, multidisciplinary approach. Int J Radiat Oncol Biol Phys 98(2):E19CrossRef

44.

Andic F, Ors Y, Davutoglu R, Baz Cifci S, Ispir EB, Erturk ME (2009) Evaluation of skin dose associated with different frequencies of bolus applications in post-mastectomy threedimensional conformal radiotherapy. J Exp Clin Cancer Res 28:41PubMedPubMedCentralCrossRef

45.

Tieu MT, Graham P, Browne L, Chin YS (2011) The effect of adjuvant postmastectomy radiotherapy bolus technique on local recurrence. Int J Radiat Oncol Biol Phys 81:e165–e171PubMedCrossRef

46.

Turner JY, Zeniou A, Williams A, Jyothirmayi R (2016) Technique and outcome of post-mastectomy adjuvant chest wall radiotherapy—The role of tissue-equivalent bolus in reducing risk of local recurrence. Br J Radiol 89:20160060PubMedPubMedCentralCrossRef

47.

Nakamura N, Arahira S, Zenda S et al (2017) Post-mastectomy radiation therapy without usage of a bolus may be a reasonable option. J Radiat Res 58(1):66–70. https://doi.org/10.1093/jrr/rrw055 CrossRefPubMedPubMedCentral

48.

Shiau A, Chiu M, Chen T, Chiou J, Shueng P, Chen S, Chen W, Kuan W (2012) SU-E-T-233: Evaluation of superficial doses for postmastectomy radiotherapy. Med Phys 39:3757. https://doi.org/10.1118/1.4735296 CrossRefPubMed

49.

Wong S, Back M et al (2012) Can radiation therapy treatment planning system accurately predict surface doses in postmastectomy radiation therapy patients? Med Dosim 37:163–169PubMedCrossRef

50.

Fischbach M, Hälg RA et al (2013) Measurement of skin and target dose in post-mastectomy radiotherapy using 4 and 6 MV photon beams. Radiat Oncol 8:270PubMedPubMedCentralCrossRef

51.

Damast S, Beal K, Ballangrud A et al (2006) Do metallic ports in tissue expanders affect postmastectomy radiation delivey? Int J Radiat Oncol Biol Phys 66(1):305–310PubMedCrossRef

52.

Thompson RC, Morgan AM (2005) Investigation into dosimetric effect of a MAGNA-SITE™ tissue expander on post-mastectomy radiotherapy. Med Phys 32(6):1640–1646PubMedCrossRef

53.

Camacho C, Pujades MC, Perez-Calatayud J, Lliso F, Carmona V, Tormo A, Ballester F (2012) Impact of the Tiloop Bra® mesh in CT images and dose delivery in breast radiotherapy. J Appl Clin Med Phys 13(2):3667. https://doi.org/10.1120/jacmp.v13i2.3667 CrossRefPubMed

54.

Piroth MD, Piroth DM, Pinkawa M, Woodruff SG, Holy R (2009) Eble MJ Immediate reconstruction with an expander/implant following ablatio mammae because of breast cancer: Side effects and cosmetic results after adjuvant chest wall radiotherapy. Strahlenther Onkol 185(10):669–674. https://doi.org/10.1007/s00066-009-2013-9 CrossRefPubMed

55.

Classen J, Nitzsche S, Wallwiener D, Kristen P, Souchon R, Bamberg M, Brucker S (2010) Fibrotic changes after postmastectomy radiotherapy and reconstructive surgery in breast cancer. A retrospective analysis in 109 patients. Strahlenther Onkol 186(11):630–636. https://doi.org/10.1007/s00066-010-2158-6 CrossRefPubMed

56.

Jagsi R, Momoh AO, Qi J, Hamill JB, Billig J, Kim HM, Pusic AL, Wilkins EG (2018) Impact of radiotherapy on complications and patient-reported outcomes after breast reconstruction. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djx148 CrossRefPubMedPubMedCentral

57.

Mithchell SD, Willey SC, Beitsch P, Feldmann S (2018) Evidence based outcomes of American Society of Breast Surgeons Nipple Sparing Mastectomy Registry. Gland Surg 7(3):247–257CrossRef

58.

Wenz F, Sperk E, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Piroth MD, Sautter-Bihl ML, Sedlmayer F, Souchon R, Fussl C, Sauer R, Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) (2014) DEGRO practical guidelines for radiotherapy of breast cancer IV: Radiotherapy following mastectomy for invasive breast cancer. Strahlenther Onkol 190(8):705–714PubMedCrossRef

59.

Mukesh MB, Duke S, Parashar D, Wishart G, Coles CE, Wilson C (2014) The Cambridge post-mastectomy (C-PMRT) index: A practical tool forpatient selection. Radiother Oncol 110(3):461–466PubMedCrossRef

60.

Li JL, Lin X, Zhunag LJ et al (2017) Establishment of a risk scoring system for predicting locoregional recurrence in T1 to T2 node negative breast cancer patients treated with mastectomy. Medicine 96(96):e7434PubMedPubMedCentral

61.

Sharma R, Bedrosian I, Lucci A et al (2010) Present-day locoregional control in patients with T1 or T2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol 17:2899–2908PubMedPubMedCentralCrossRef

Titel: Radiotherapy after skin-sparing mastectomy with immediate breast reconstruction in intermediate-risk breast cancer
Indication and technical considerations
verfasst von: Thomas Hehr
René Baumann
Wilfried Budach
Marciana-Nona Duma
Jürgen Dunst
Petra Feyer
Rainer Fietkau
Wulf Haase
Wolfgang Harms
David Krug
Marc D. Piroth
Felix Sedlmayer
Rainer Souchon
Frederick Wenz
Rolf Sauer
Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO)
Publikationsdatum: 26.08.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 11/2019
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-019-01507-9

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Radiotherapy after skin-sparing mastectomy with immediate breast reconstruction in intermediate-risk breast cancer

Indication and technical considerations